Nanobiotix S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Nanobiotix S.A. for the month of February 2026. The filing, dated February 25, 2026, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The company is headquartered in Paris, France, and files annual reports under Form 20-F.
Financial Metrics
The provided filing text does not contain specific financial data. No values for revenue, profit, cash flow, margins, debt, or liquidity are disclosed in this document. The filing acts solely as a conduit for the attached press release, the content of which is not included in the source text.
Material Changes
The filing text does not provide information regarding material changes versus prior comparable periods. Any such updates would be contained within the referenced press release (Exhibit 99.1), which is not present in the input data.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not detailed in this filing. The document confirms the issuance of a press release but does not summarize its contents.
Key Facts for Investor Verification
- The filing is a procedural Form 6-K referencing an external press release dated February 25, 2026.
- No financial metrics or operational updates are included in the text of this specific filing.
- Investors must locate and review Exhibit 99.1 (the press release) to obtain the actual news or data announced by the company.
- The report was signed by Bart Van Rhijn, Chief Financial Officer.